Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149925 (small cell lung cancer)
 6,491 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The usual form of chemotherapy of metastatic small cell lung cancer gives a 50% objective response with a mean survival of 7-8 months. We have tested a new antimitotic drug using pirarubicin alone in 26 patients. After the second treatment we noticed a response level of 12% with moderate toxicity. Then, we undertook classical chemotherapy using cisplatin-V16. After 3 doses the response level was 50% with a median survival of 32 weeks. In our study the use of a single drug pirarubicin in metastatic small cell cancer did not appear to worsen the chance of survival in patients if polychemotherapy was carried out immediately in cases which failed on the single drug. Our monotherapy did not appear to induce resistance to affective polychemotherapy. This method applied carefully to patients with metastatic disease with a strict follow up may be utilised in the assessment of the efficacy of the newer antimitotic drugs.
Rev Mal Respir 1992
PMID:[A phase II trial of pirarubicin in untreated disseminated small cell lung cancer. A cooperative study of the French Pneumo-Cancerology Group]. 131 4

The histopathology criteria which could be taken into account in devising the best strategy in tumor extension search in non small cell lung carcinoma (NSCLC), were examined. First, the differential diagnosis between primary and metastatic carcinoma is impossible on histological basis in squamous carcinomas, and in mucinous adenocarcinoma which share several features with tumors from digestive tract including mucus secretion, morphological pattern and ultrastructural signs. The recognition of cells which are unique in the lung (Clara cells, pneumonocytes II) guarantees the pulmonary origin of a non mucinous adenocarcinoma. In other cases such as large cell carcinomas, the diagnosis of metastasis can be achieved in some instances in using a large panel of immunohistochemical markers. Secondly, the expression of neuroendocrine markers in NSCLC could lead to an extension search procedure identical to that of SCLC, if it can be confirmed that they share their poor prognosis and chemosensibility. Finally, there is no statistical evidence of a difference in the extrathoracic extension between well and poorly differentiated forms of squamous carcinoma and adenocarcinoma. Only one exception should be made for the recently described basaloid carcinoma of the lung which extension and prognosis are more severe than in other NSCLC.
Rev Mal Respir 1992
PMID:[Do pathologic-anatomic data influence the staging of non-small cell bronchial cancer?]. 133 79

The proliferation of the bronchial epithelium and tumors associated with this tissue is controlled by various growth factors. The main factor is Gastrin Releasing Peptide (GRP), the human counterpart of the amphibian bombesin. These neuropeptides also act as neuromediators and gut hormones. All peptides of this family share a conserved C terminal sequence which is required for biological activity. The determination of this sequence has provided the basis for the design of specific agonist and antagonist peptides and for the generation of monoclonal antibodies (Mab). GRP interacts with a receptor coupled to a G protein and the signalling process leads to the activation of phospholipase C and kinases, and the mobilization of calcium. GRP promotes the proliferation of foetal and adult bronchial epithelium and of small cell lung cancer (SCLC) cells. GRP is also an autocrine growth factor for some SCLC cell lines. The growth of these lines is reduced in vitro and in vivo by MAb and specific antagonists. Hyperplasia of GRP producing cells has been shown in various lung diseases in adults and children. Pharmacological data on GRP suggest that its antagonists could be used in the treatment of SCLC (in addition to chemotherapy) and of interstitial lung disease. The cloning of the GRP receptor should facilitate the design of specific and potent antagonists of the peptide.
Rev Mal Respir 1992
PMID:[The role of gastrin releasing peptide as a lung growth factor]. 156 25

Thymidine kinase (TK) is a biological marker recently used in diagnosis and monitoring of pulmonary and mediastinal malignant neoplasms. Authors report more recent clinical evidences of literature and, in the meanwhile, they report their personal experiences about a 20 patients group suffering of lung cancer and Hodgkin disease. Their study demonstrates a good sensitivity of TK as biological marker of SCLC and a lower sensitivity in case of NSCLC and Hodgkin disease. It has been possible to contribute to establishment of normal range values, on account of 10 healthy volunteer group blood sample assays.
Arch Monaldi Mal Torace
PMID:[Thymidine kinase as a biological marker in neoplasms of the lung and mediastinum]. 166 60

Over the past ten years there has been fundamental progress in molecular biology, i.e. concerning the structure and function of genes. The understanding and diagnosis of several diseases, in particular those of the respiratory system, have been profoundly affected and changed. For example alpha-1-antitrypsin deficiency and the emphysema which results have now been dissected down to a molecular level and characterised by anomalies of certain critical portions of the gene coding for this protein. The same thing is found in cystic fibrosis where, thanks to recent technical progress, it is now possible to make a positive diagnosis in most unaffected carriers. The importance of molecular biology in lung cancer is equally established, and in small cell lung cancer one can already isolate a sub group of cancers presenting with an abnormal amplification of the c-myc oncogene. Finally, the role of inflammatory cells, in particular macrophages, in pulmonary fibrosis is best understood by studying the expression by macrophages of the genes coding for mediators which alter the replication of fibroblasts.
Rev Mal Respir 1990
PMID:[Application of molecular biology techniques to pneumology]. 217 33

Three hundred and four cases of small cell lung cancer diagnosed histologically were included in a randomised multi-centre trial (23 centres) from 1st January 1983 to the 30 September 1985, with no clinical criteria for exclusion. The clinical and laboratory data were taken from the initial assessment of the patients in the trial, and were compared with those in the literature. The sex ratio was 10:1, only 27 were women (9%) and all were less than 70. The mean aged was 60 +/- 10 (extremes 33 to 84 years) and 80% of the population was from 40 to 70 years. Tobacco consumption was virtually constant, only 7 were non-smokers and 7% of patients smoked less than 20 packs/year; indeed consumption was very heavy with a mean of 44 +/- 23 packs/years. 14% of cases were discovered on systematic radiological examination, but 39% of these asymptomatic patients already had disseminated disease. For the 304 patients overall, despite a very variable degree of dissemination from one patient and one centre to another, 163 (54%) had disseminated disease at the outset and 141 (46%) were apparently localised. The initial metastases were often multiple: extra-thoracic nodes (21%), hepatic (23%), osseous (20%), bone marrow (23%), cerebral (9%), and others (9%); these frequencies are underestimated in view of the fact that the investigations were not over-extensive. The serum carcino embryonic antigen levels were abnormal in 32% of cases. Fibroscopy remains the main diagnostic method to provide the histological proof for 90% of patients, but 4% had thoracotomies (of whom 3% were diagnostic thoracotomies).(ABSTRACT TRUNCATED AT 250 WORDS)
Rev Mal Respir 1987
PMID:[Initial clinical and paraclinical findings in 304 small cell broncho-pulmonary cancers of the 01 PC 83 trial]. 282 23

Progress achieved in the understanding of small cell lung cancer (SCLC) include: the establishment and characterization of cell lines with the identification of a variant type with poor prognosis; the use of non-specific biochemical markers such as neuron specific enolase (NSE) and calcitonin; the generation of monoclonal antibodies (MoAbs) directed against SCLC antigens; growth factors including GRP and IGF. GRP or human bombesin produced by the tumor cells favours their own growths; in cytogenetics, with the observation of a characteristic chromosomal abnormality: the deletion of the short arm of chromosome 3 (3p 14-23). The region deleted is currently under study to identify the genes potentially involved in the oncogenesis of SCLC. the activation of several oncogenes: C-myc, N-myc, L-myc, Myb, Raf-1. The amplification of C-myc favors the tumor cell progression and is related to a bad prognosis. This biological approach has confirmed the neuroendocrine origin of these tumor cells (as a result of protein studies of the cytoskeleton and of MoAbs); it has allowed the use of tumor markers in the diagnosis and work-up of SCLC and the consideration of new therapeutic approaches. Current studies concern the deletion of 3p- and the integration of the cytogenetic data, growth factors and oncogenes in a coherent model of the genesis of SCLC.
Rev Mal Respir 1988
PMID:[Recent progress in the biology of small cell bronchial carcinoma]. 284 57

We report a case of small cell lung cancer in a 17 year-old man. He was admitted to our unit suffering from a two month history of pain left shoulder. Chest X-rays showed a large round mass in the left upper lobe. The chest CT scan revealed a tumor with evidence of first left rib involvement. Histological examination, after surgical biopsy revealed small cell carcinoma, confirmed by two independent pathological physicians. Small cell lung carcinoma is very rare in the under 20 year age group and we compare this case with other types of lung cancer in young patients described in the literature.
Rev Mal Respir 1994
PMID:[Small cell bronchial cancer in a 17-year-old young man]. 783 15

Alternatively to the usual evaluation summary, a characteristic of small cell lung cancer, is the probability of significant diffuse metastases; the prognosis is directly linked to the extent of these metastases. Moreover, the assessment of the initial extension becomes heavier and more costly as investigations continue and each new technology appears. In order to evaluate the contribution of each examination, a classification has been established as a function of the time-scale to obtain the results, of the technology involved, or whether the investigation is painful or not and any likelihood of iatrogenic side-effects. An assessment in three stages is proposed to achieve the most effective and cheapest diagnosis possible. In relation to the usual technique of assessment this sequential approach allows for a 27% reduction in the time-scale for the diagnosis of diffuse disease, 51.3% in terms of technical involvement, 46.3% in terms of pain and discomfort and 53.9% in terms of iatrogenic potential. At the same time a reduction in cost of 47.5% is observed.
Rev Mal Respir 1993
PMID:[Clinical and economic evaluation of the initial assessment of small cell cancer of the lung. Alternatives to classic evaluation. LGTO. The Lyon Group of Thoracic Oncology]. 825 31

Pretherapeutic prognostic factors were studied retrospectively in 112 consecutive patients diagnosed as small cell lung cancer between January 1st 1986 and December 30th 1990 in our department. Mean age of the population was 59.3, 89.3% were males. Median survival time of the whole population is 11.66 months. It is 15.3 months for the 48 patients with limited disease stage and 9.74 months for 64 patients with extensive disease stage. Among the patients with limited disease stage, those with supraclavicular lymph nodes had a significantly shorter survival (p < 0.001). Univariate analysis of survival identified age, performances status, weight loss, T, N, bone and liver involvement, serum sodium, albumin and sedimentation rate as prognostic factors. The final model in multivariate analysis of survival includes for the patients with performance status < or = 70, extent of disease as an independent prognostic factor and for the patients with performance status < 70, extent of disease, serum sodium and albumin.
Rev Mal Respir 1993
PMID:[Pre-therapeutic prognostic factors of survival in small cell bronchial cancer. Retrospective study in a series of 112 patients]. 838 69


1 2 3 4 Next >>